A338840 Share Price Performance
₩10,760.00
2600.00 (31.86%)
Price ₩10,760.00
Share Price₩10,760.00
A338840 Community Narratives
There are no narratives available yet.
Recent A338840 News & Updates
No updates
Y-Biologics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -448.13
- Gross Margin
- 74.67%
- Net Profit Margin
- -133.25%
- Debt/Equity Ratio
- 2.8%
Y-Biologics, Inc. Competitors
About A338840
- Founded
- 2007
- Employees
- n/a
- CEO
- WebsiteView website
Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by declines in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. As for the longer term, the market has actually risen by 26% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading